A Prospective Study of Exosome Therapy for Androgenetic Alopecia

This study found that treating patients with androgenetic alopecia using exosomes from adipose tissue stem cells over 24 weeks significantly increased hair density and patient satisfaction without severe adverse effects, suggesting a promising alternative treatment for hair loss.

This review highlights the potential of exosomes, particularly their microRNA components, as promising candidates for developing effective hair loss treatments by exploring their roles in hair follicle development and regeneration.

This study found that androgenic alopecia significantly impaired quality of life among men in the Eastern Province of Saudi Arabia, with younger males and those diagnosed by a doctor experiencing greater quality of life issues, particularly in the symptoms domain.

This study using human and animal models found that adipose-derived stem cell exosomes promoted hair growth and counteracted dihydrotestosterone's inhibitory effects, suggesting potential therapeutic applications for androgenetic alopecia.

This study observed that in a mouse model of androgenetic alopecia, treatments with LTF, 5% minoxidil, and LTF-DPC-EXO significantly promoted hair regeneration compared to the model group, potentially through modulation of the PI3K/AKT signaling pathway.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This review examines the efficacy of various novel treatments for androgenetic alopecia, including oral minoxidil and platelet-rich plasma, suggesting potential benefits but emphasizing the need for further high-quality clinical trials to thoroughly evaluate their effectiveness.

This review found that while preclinical studies highlight the potential benefits of exosome therapeutics for hair loss, clinical evidence on their safety and effectiveness for alopecia is currently lacking, requiring further research.

This review highlights that androgenetic alopecia significantly impacts psychological well-being and quality of life, emphasizing the need for integrated psychological support alongside dermatological treatment.

This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

This article reviews current diagnostic and treatment approaches for androgenetic alopecia but reports no new results, focusing on its progression and medical management options.